Key Points
A combination of stigma and lack of insurance coverage can make it hard for people to access weight loss drugs...
A new medication has the potential to be even more effective for weight loss than currently trending drugs like Ozempic and Wegovy if patients can access it...
Tirzepatide, a once-weekly injection currently sold under the brand name Mounjaro, is being studied for itsdramatic effects on appetite and blood sugar control, helping patients lose up to 20 percent of their body weight, on average, in clinical trials...
One of the patients in the first clinical trial, a 47-year-old woman named Tara Rothenhoefer, told Insider that she lost a total of 176 pounds on tirzepatideandthe medication "changed her life."..
She was finally able to obtain a prescription for Mounjaro through an online prescriber, and the weight started coming off again.While she's now nearing her goal weight, and hopes to maintain there, she worries that it will be an uphill battle if she loses access to tirzepatide...
You might be interested in
The next game-changing weight loss drug just moved closer to FDA approval
27, Apr, 23In a new study, patients on tirzepatide (Mounjaro) lost nearly 16% of their body weight in 16 months.
Mounjaro: Weight loss drug suppresses appetite, awaits FDA approval
17, Mar, 23Tirzepatide, sold as Mounjaro, is a diabetes medication being considered for use to treat obesity, like the related drug semaglutide.
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
Tirzepatide, another diabetes drug cleared for weight loss in US, yet to get regulator nod in India
20, Nov, 23In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
27, Jun, 23Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.
Ozempic competitor Mounjaro helped woman lose 176 lbs
18, May, 23Tirzepatide, brand name Mounjaro, may be more effective for weight loss than Ozempic: patients lost up to 5% more weight with it in a clinical study.
Tirzepatide weight loss patients lost 64 lbs. on average: study
15, Oct, 23Using tirzepatide for weight loss was most effective with diet and exercise changes. It may be more effective than other GLP-1 drugs like semagultide.
Tirzepatide approved for weight loss, stronger than semaglutide
08, Nov, 23Mounjaro is a stronger drug than Ozempic. Now, there's a version of the drug available for patients who aren't diabetic.
Retatrutide patients lose more weight than Ozempic, Wegovy, or Mounjaro
27, Jun, 23The new weight loss drug, in development by Eli Lilly, could be as powerful as bariatric surgery patients with obesity lost 24% of their body weight.
Doctors share their biggest concerns about Ozempic, from muscle loss to hollowed faces
29, Mar, 23Ozempic, also known as semaglutide or Wegovy is a trending drug used for weight loss but doctors worry the hype could have health consequences.